Regenxbio Inc is a biotechnology company focused on advancing the field of gene therapy for the treatment of rare and debilitating diseases. The company specializes in developing innovative therapies that utilize its proprietary AAV (adeno-associated virus) gene delivery technology, which aims to correct genetic defects and restore normal function at the cellular level. Regenxbio is committed to addressing unmet medical needs through its robust pipeline of product candidates, targeting various conditions, including inherited retinal diseases and neurodegenerative disorders. By harnessing the power of gene therapy, Regenxbio seeks to transform treatment options and improve the quality of life for patients. Read More
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile.
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, ETFs, and stocks that moved the market higher, as well as the market segments that defied the trend by moving lower.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.
